LASIX
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Mar 1968
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
LASIX by Sanofi is 12. Approved for edema in adult patients with chronic heart failure. First approved in 1968.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LASIX (furosemide) is a loop diuretic small molecule that inhibits sodium and chloride reabsorption in the proximal and distal tubules and loop of Henle, producing potent diuresis. It is indicated for edema in adult patients with chronic heart failure (NYHA Class II–III). Lasix ONYU is a novel subcutaneous formulation that delivers comparable diuresis to intravenous dosing with an 8+ hour duration of effect.
$0.61MPart D
LOE ApproachingProduct approaching loss of exclusivity signals potential downsizing of brand teams; priority shifts toward lifecycle extension and specialty/hospital channel focus.
Mechanism of Action
12.1 Mechanism of Action Furosemide primarily inhibits the reabsorption of sodium and chloride in the proximal and distal tubules and in the loop of Henle. The high degree of diuresis is largely due to the unique site of action. The action on the distal tubule is independent of any inhibitory…
Worked on LASIX at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.